Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00174421
NCT00174421CompletedPhase 3

Genotropin in Short Children Born Small for Gestational Ag - A Long-Term Study in Belgium

Pfizer0 sites36 target enrollmentStarted: April 2001Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Pfizer
Enrollment
36
Primary Endpoint
Final height, compared to the expected familial target height
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This trial evaluates whether long-term treatment with Genotropin normalizes final (adult) height in short children born small for gestational age

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Participation in the 90-080 study

Exclusion Criteria

  • •Any severe, acute or chronic disease
  • •Any other identifiable reason for short stature

Outcomes

Primary Outcomes

Final height, compared to the expected familial target height

Secondary Outcomes

  • Body weight, body mass index at final height; adverse events and assessment of hematological and clinical chemistry

Investigators

Sponsor
Pfizer
Sponsor Class
Industry

Similar Trials

Completed
Phase 3
Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational AgeGrowth Disorders
NCT00174408Pfizer110
Completed
Phase 4
Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)Short Stature Born Small for Gestational Age (SGA)
NCT01859949Pfizer62
Completed
Phase 2
Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With SomatropinIdiopathic Short Stature
NCT00488124University of Erlangen-Nürnberg Medical School120
Completed
Phase 3
Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth RetardationGrowth DisordersIntrauterine Growth Retardation
NCT01073605Pfizer208
Terminated
Phase 2
Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's DiseaseArthritis, Juvenile RheumatoidCrohn Disease
NCT00511329Nationwide Children's Hospital10
Treatment Of Short Stature With Genotropin... | Clinical Trial